CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes based on the company’s proprietary in vitro models of viral liver infection, including Hepatitis B. The new facility will additionally comprise BSL-2 laboratories, an engineering laboratory and office space.
- MPS World Summit Round-up 27th June 2022
- CN Bio appoints Dr Paul Brooks as Chief Business Officer 24th May 2022
- CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit 26th April 2022